MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Clearside Biomedical Net Income 2011-2026 | CLSD
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Clearside Biomedical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -32.5 M | -32.9 M | 376 K | -18.2 M | -30.8 M | -82.8 M | -59 M | -25.9 M | -17.6 M | -10.2 M | -7.25 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 376 K | -82.8 M | -28.8 M |
Quarterly Net Income Clearside Biomedical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.97 M | -4.5 M | -8.22 M | - | -7.69 M | -7.59 M | -11.8 M | - | -9.27 M | -9.11 M | -9.28 M | - | -7.83 M | -7.81 M | -7.64 M | - | -4.89 M | -6.1 M | -7.35 M | - | -2.43 M | -5.75 M | -2.91 M | -3.1 M | -6.54 M | -5.73 M | -15.4 M | -21.6 M | -23.9 M | -20.7 M | -16.6 M | -16.5 M | -18.3 M | -13.8 M | -10.4 M | -9.69 M | -5.64 M | -5.1 M | -5.45 M | -5.17 M | -3.48 M | -5.33 M | -3.76 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2.43 M | -23.9 M | -9.01 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Anika Therapeutics
ANIK
|
-82.7 M | $ 14.93 | 0.88 % | $ 219 M |  USA |
 |
Aptorum Group Limited
APM
|
-4.27 M | $ 0.93 | 0.51 % | $ 5.07 M |  China |
 |
Aquestive Therapeutics
AQST
|
-83.8 M | $ 4.14 | 0.36 % | $ 443 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-65.8 M | $ 8.39 | 4.5 % | $ 230 M |  Israel |
 |
Ardelyx
ARDX
|
-61.6 M | $ 6.06 | 1.94 % | $ 1.46 B | USA |
 |
argenx SE
ARGX
|
-408 M | $ 749.68 | 0.44 % | $ 25 B |  Niderland |
 |
Arcutis Biotherapeutics
ARQT
|
-16.1 M | $ 23.93 | 1.27 % | $ 3.04 B | USA |
 |
Arvinas
ARVN
|
-80.8 M | $ 11.36 | 4.7 % | $ 805 M | USA |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M | China |
 |
Arrowhead Pharmaceuticals
ARWR
|
-1.63 M | $ 61.99 | 1.57 % | $ 8.29 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B |  France |
 |
Assembly Biosciences
ASMB
|
-6.12 M | $ 29.09 | 0.28 % | $ 326 M | USA |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M | France |
 |
Actinium Pharmaceuticals
ATNM
|
-33.9 M | $ 1.13 | 15.26 % | $ 35.3 M | USA |
 |
Atossa Therapeutics
ATOS
|
-34.8 M | $ 5.19 | -3.36 % | $ 44.7 M | USA |
 |
Atara Biotherapeutics
ATRA
|
32.7 M | $ 5.0 | 0.2 % | $ 62.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
211 M | $ 16.05 | 2.79 % | $ 2.16 B |  Canada |
 |
Autolus Therapeutics plc
AUTL
|
-288 M | $ 1.41 | -0.35 % | $ 375 M | Britain |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | USA |
 |
Axon Enterprise
AXON
|
377 M | $ 411.97 | -0.2 % | $ 31.2 B | USA |
 |
Aytu BioScience
AYTU
|
-13.6 M | $ 2.65 | -1.12 % | $ 16.6 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-22.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
BioCardia
BCDA
|
-8.23 M | $ 1.18 | -1.67 % | $ 7.87 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
-88.9 M | $ 9.59 | 6.26 % | $ 1.98 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-48.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-49.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-46.4 M | $ 3.05 | 1.51 % | $ 260 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-847 M | $ 9.46 | -3.47 % | $ 612 M | USA |
 |
BioVie
BIVI
|
-17.5 M | $ 1.46 | 2.81 % | $ 2.16 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-27.1 M | $ 2.32 | 4.98 % | $ 908 M | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
349 M | $ 56.04 | 0.96 % | $ 10.7 B | USA |
 |
BioNTech SE
BNTX
|
10.3 B | $ 91.64 | 0.5 % | $ 27.2 B | Germany |
 |
Aravive
ARAV
|
-76.3 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioXcel Therapeutics
BTAI
|
-69.9 M | $ 1.18 | -0.42 % | $ 14.4 M | USA |
 |
Burford Capital Limited
BUR
|
172 M | $ 4.5 | 8.57 % | $ 683 M | Britain |